

July 13, 2006

Charles Rose
Director, American Association for Nuclear Cardiology, Inc.
5660 Airport Boulevard, Suite 101
Boulder, CO 80301

SUBJECT: LETTER DATED MAY 25, 2006

Dear Mr. Rose:

I am responding to your letter, dated May 25, 2006, in which you requested a response from the U.S. Nuclear Regulatory Commission (NRC) as to preceptor attestation requirements. Specifically, you stated that it is your understanding that to become an authorized user under 10 CFR 35.290, an individual must provide the appropriate preceptor attestation.

The written attestation requirements described in 10 CFR 35.290(c)(2) is required of physicians seeking to become authorized users for §35.200 uses by the board certification pathway, described in §35.290(a), as well as physicians seeking authorized user status under the alternate pathway described in §35.290(c)(1).

For further information or for questions, please contact me or Ms. Cindy Flannery, Team Leader of the Division of Industrial and Medical Nuclear Safety's Medical Radiation Safety Team at (301) 415-0223, or via e-mail at cmf@nrc.gov.

Sincerely,

/RA/

Thomas H. Essig, Chief
Materials Safety & Inspection Branch
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards

July 13, 2006

Charles Rose
Director, American Association for Nuclear Cardiology, Inc.
5660 Airport Boulevard, Suite 101
Boulder, CO 80301

SUBJECT: LETTER DATED MAY 25, 2006

Dear Mr. Rose:

I am responding to your letter, dated May 25, 2006, in which you requested a response from the U.S. Nuclear Regulatory Commission (NRC) as to preceptor attestation requirements. Specifically, you stated that it is your understanding that to become an authorized user under 10 CFR 35.290, an individual must provide the appropriate preceptor attestation.

The written attestation requirements described in 10 CFR 35.290(c)(2) is required of physicians seeking to become authorized users for §35.200 uses by the board certification pathway, described in §35.290(a), as well as physicians seeking authorized user status under the alternate pathway described in §35.290(c)(1).

For further information or for questions, please contact me or Ms. Cindy Flannery, Team Leader of the Division of Industrial and Medical Nuclear Safety's Medical Radiation Safety Team at (301) 415-0223, or via e-mail at cmf@nrc.gov.

Sincerely,

/RA/

Thomas H. Essig, Chief
Materials Safety & Inspection Branch
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards

DISTRIBUTION:

IMNS r/f CFlannery

ML061950363

OFC	MSIB	MSIB	MSIB
NAME	CFlannery	SWastler	TEssig
DATE	7 /13 /06	7/ 13 /06	7 / 14 /06

OFFICIAL RECORD COPY